Calculated Non-HDL Cholesterol Includes Cholesterol in Larger Triglyceride-Rich Lipoproteins in Hypertriglyceridemia.
hypertriglyceridemia
non-HDL cholesterol
triglyceride-rich lipoproteins
Journal
Journal of the Endocrine Society
ISSN: 2472-1972
Titre abrégé: J Endocr Soc
Pays: United States
ID NLM: 101697997
Informations de publication
Date de publication:
01 Jan 2020
01 Jan 2020
Historique:
received:
30
09
2019
accepted:
30
10
2019
entrez:
4
2
2020
pubmed:
6
2
2020
medline:
6
2
2020
Statut:
epublish
Résumé
Calculated non-high-density lipoprotein (HDL) cholesterol (non-HDLC) should selectively include cholesterol from atherogenic lipoproteins to be a reliable risk marker of cardiovascular disease. In hypertriglyceridemia (HTG), there is increased abundance of larger and less atherogenic triglyceride-rich lipoproteins (TRL), namely, larger very-low-density lipoproteins (VLDL), and chylomicrons. We aim to demonstrate that serum triglyceride (TG) level has a substantial impact on non-HDLC's ability to represent cholesterol from atherogenic lipoproteins, even though TG is not part of the calculation for non-HDLC. Analysis of lipid profile data. Lipid Clinic patient cohort, and Biochemistry Laboratory patient cohort. 7,492 patients in the Lipid Clinic cohort with baseline lipid profiles documented prior to starting lipid-lowering medications and 156,311 lipid profiles from The Ottawa Hospital Biochemistry Laboratory cohort. None. Our modeling process includes derivation of TG-interval-specific lipoprotein composition factor (LCF) for TRL, which represents the mass ratio of cholesterol to TG in TRL. A high LCF indicates that the TRLs are mainly the cholesterol-rich atherogenic remnant lipoproteins. A low LCF indicates that the TRLs are mainly the TG-rich larger VLDL and chylomicrons. As serum TG increases, there is progressive decline in the LCF for TRL, which indicates that the calculated non-HDLC level reflects progressive inclusion of cholesterol from larger TRL. This is shown in both cohorts. Calculated non-HDLC is influenced by TG level. As TG increases, non-HDLC gradually includes more cholesterol from larger TRL, which are less atherogenic than LDL and remnant lipoproteins.
Identifiants
pubmed: 32010872
doi: 10.1210/jendso/bvz010
pii: bvz010
pmc: PMC6986683
doi:
Types de publication
Journal Article
Langues
eng
Pagination
bvz010Informations de copyright
© Endocrine Society 2019.
Références
J Lipid Res. 1996 Apr;37(4):693-707
pubmed: 8732771
Circulation. 2019 Jun 18;139(25):e1082-e1143
pubmed: 30586774
Proc Natl Acad Sci U S A. 1977 Mar;74(3):837-41
pubmed: 265578
Ann Intern Med. 2019 May 7;170(9):626-634
pubmed: 31035285
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
Adv Lipid Res. 1968;6:1-68
pubmed: 4179999
J Clin Lipidol. 2015 Mar-Apr;9(2):129-69
pubmed: 25911072
J Clin Lipidol. 2014 Jan-Feb;8(1):29-60
pubmed: 24528685
J Am Coll Cardiol. 2014 Dec 16;64(23):2525-40
pubmed: 25500239
Arterioscler Thromb Vasc Biol. 1997 Dec;17(12):3542-56
pubmed: 9437204
Endocr Pract. 2017 Apr;23(Suppl 2):1-87
pubmed: 28437620
J Clin Invest. 1984 Dec;74(6):2178-92
pubmed: 6511922
Circ Res. 2016 Feb 19;118(4):547-63
pubmed: 26892957
JAMA Cardiol. 2018 Aug 1;3(8):749-753
pubmed: 29898218
Crit Rev Clin Lab Sci. 1998 Dec;35(6):489-516
pubmed: 9885773
J Clin Lipidol. 2015 Nov-Dec;9(6 Suppl):S1-122.e1
pubmed: 26699442
N Engl J Med. 1967 Jan 12;276(2):94-103 contd
pubmed: 5332928
Can J Cardiol. 2016 Nov;32(11):1263-1282
pubmed: 27712954
J Lipid Res. 2018 Jul;59(7):1266-1275
pubmed: 29769239
Eur Heart J. 2016 Oct 14;37(39):2999-3058
pubmed: 27567407
JAMA. 2013 Nov 20;310(19):2061-8
pubmed: 24240933
Curr Opin Lipidol. 2014 Dec;25(6):461-7
pubmed: 25340478
J Clin Invest. 1973 Jul;52(7):1578-85
pubmed: 4352459